Society guideline links: Rheumatoid arthritis

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately:

●(See "Society guideline links: NSAID-related ulcer complications".)

●(See "Society guideline links: Sjögren's disease".)

●(See "Society guideline links: Undifferentiated early inflammatory arthritis".)

●(See "Society guideline links: Juvenile idiopathic arthritis".)

International

●International Task Force: Recommendations for treating rheumatoid arthritis to target, 2014 update (published 2016)

Canada

●Canadian Rheumatology Association (CRA): Recommendations for management of RA

•CRA: Recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs (2012)

•CRA: Recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs – Part II safety (2012)

United States

●American College of Rheumatology (ACR): Clinical practice guidelines on rheumatoid arthritis

•ACR: Guideline for the treatment of rheumatoid arthritis (2021)

•ACR: Recommended patient-reported functional status assessment measures in rheumatoid arthritis (2019)

•ACR: Recommended rheumatoid arthritis disease activity measures, update (2019)

•ACR: Updated guideline for the management of rheumatoid arthritis – Project plan (2018)

•ACR: Guideline for the treatment of rheumatoid arthritis (2015)

•ACR: Recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis, 2008 update (published 2012)

●American College of Radiology (ACR): ACR Appropriateness Criteria on chronic extremity joint pain-suspected inflammatory arthritis (2016)

Europe

●European League Against Rheumatism (EULAR): Recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, 2019 update (published 2020)

●EULAR: Recommendations for physical activity in people with inflammatory arthritis and osteoarthritis (2018)

●EULAR: Recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders, 2015/2016 update (published 2017)

●EULAR: Recommendations for the management of early arthritis, 2016 update (published 2017)

●EULAR: Recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis (2013)

United Kingdom

●National Institute for Health and Care Excellence (NICE): Guideline on rheumatoid arthritis in adults – Management (2018, updated 2020)

●NICE: Quality standard on rheumatoid arthritis in over 16s (2013, updated 2020)

●British Society for Rheumatology (BSR): Biologic DMARD safety guidelines in inflammatory arthritis (2019)

●NICE: Diagnostics guidance on the therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (2019)

●Choosing Wisely UK: British Society of Rheumatology – Patients with suspected inflammatory arthritis should be referred to rheumatology without delay. Rheumatoid factor and CCP/ACPA are important, but should be avoided as screening tests. A negative result does not exclude rheumatoid arthritis, nor does a positive result equate to a diagnosis of rheumatoid arthritis. Repeat testing is not normally indicated (2016)

●Scottish Intercollegiate Guidelines Network (SIGN): A national clinical guideline for the management of early rheumatoid arthritis (2011)

India

●Asia Pacific League of Associations for Rheumatology (APLAR): Recommendations for treatment of rheumatoid arthritis, 2018 update (published 2019)

Australia–New Zealand

●Asia Pacific League of Associations for Rheumatology (APLAR): Recommendations for treatment of rheumatoid arthritis, 2018 update (published 2019)

Japan

●[In Japanese] Japanese College of Rheumatology (JCR): A guidance for the use of tofacitinib in rheumatoid arthritis (RA) (2023)

●[In Japanese] JCR: A guide to the use of TNF inhibitors in rheumatoid arthritis (RA) (2023)

●[In Japanese] JCR: Guidance for abatacept use in rheumatoid arthritis (RA) (2023)

●[In Japanese] JCR: Guidance for the use of IL-6 inhibitors for rheumatoid arthritis (RA) (2023)

●[In English] JCR: Drug treatment algorithm and recommendations from the 2020 update of the clinical practice guidelines for the management of rheumatoid arthritis – Secondary publication (published 2022)

●[In Japanese] JCR: Guide to using denosumab for rheumatoid arthritis (2020)

●[In English] Asia Pacific League of Associations for Rheumatology (APLAR): Recommendations for treatment of rheumatoid arthritis, 2018 update (published 2019)

●[In English] JCR: Guideline for the use of methotrexate in patients with rheumatoid arthritis (2019)

●[In Japanese] Choosing Wisely Japan: Rheumatoid arthritis treatment – Nonbiological agents preferred as first choice (2016)

●[In Japanese] JCR: Methotrexate (MTX) practice guideline for the treatment of rheumatoid arthritis, revised edition (2016)

●[In Japanese] JCR: Rheumatoid arthritis practice guidelines (2014)